Janux Therapeutics up after nominating cancer therapy in Bristol Myers deal

Bristol-Myers Squibb Co

01/04/2026 13:29

** Shares of drug developer Janux Therapeutics JANX.O up 1.1% to $14.05 premarket

** Co says it has nominated a development candidate under its global licensing agreement with Bristol Myers Squibb BMY.N, triggering a $35 million milestone payment

** Under the deal, Janux is responsible for conducting preclinical development of the experimental treatment using its platform that targets an undisclosed solid‑tumor antigen expressed across multiple cancer types

** Janux is eligible to receive additional development, regulatory and commercial milestone payments, as well as tiered royalties on global product sales

** Up to last close, JANX up 0.7% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))